



**Supplementary Figure 1: Transmission electron microscopy micrographs of  $P_{BAD} pel$  and PA14 strains show normal cell morphologies.** Related to Figure 2. (A)  $P_{BAD} pel$  (B) PA14 strains. Scale bars = 1  $\mu m$ .  $P_{BAD} pel$ , PAO1  $\Delta wspF \Delta psl P_{BAD} pel$ .



**Supplementary Figure 2: Western blot probing for PelA expression levels in indicated  $P_{BAD} pel$  derived strains.** Related to Figure 4. The molecular weight is indicated in kilodaltons in the MW lane on top of the marker band. The molecular weights of proteins are as follows: PelA, 101.1 kDa and PilF, 28.5 kDa.  $P_{BAD} pel$ , PAO1  $\Delta wspF \Delta psI P_{BAD} pel$ , MW, molecular weight marker.


**A** $P_{BAD}pel$ 

WT

 $\Delta pelF$  $\Delta pelA$  $\Delta pelA$   
 $:: pelA$  $\Delta pelA$   
 $:: pelA^{E218A}$ **B**


PA14

WT

 $\Delta pelF$  $\Delta pelA$  $\Delta pelA+$   
 $pelA$  $pelA^{E218A}$ 

**Supplementary Figure 3: PelA hydrolase mutant is more flocculent than wild type.** Related to Figure 4. Overnight cultures of indicated strains grown to mid-log phase at 25°C and 220 RPM, transferred to an Eppendorf tube, left to sit statically for 60 min to sediment.  $P_{BAD} pel$ , PAO1  $\Delta wspF \Delta psi P_{BAD} pel$ .

PA14



Supplementary Figure 4: Congo red colony morphologies of PA14 strains over several days. Related to Figure 5.

**Supplementary Table 1: Bacterial strains used in this study.**

Strains	Genotype or relevant characteristics <sup>1</sup>	Source
<i>Pseudomonas aeruginosa</i>		
PAO1	Wild type strain from Colin Manoil, genome re-sequenced	(1)
PAO1 $\Delta_{wspF}$ $\Delta_{psl}$ $P_{BAD}pel$	In-frame deletion of <i>wspF</i> , polar deletion of <i>pslBCD</i> , <i>araC-P<sub>BAD</sub></i> inserted upstream of <i>pelABCDEFG</i>	(2)
JJH879	PAO1 $\Delta_{wspF}$ $\Delta_{psl}$ $P_{BAD}pel$ $\Delta_{pelA}$	This study
JJH885	PAO1 $\Delta_{wspF}$ $\Delta_{psl}$ $P_{BAD}pel$ $\Delta_{pelF}$	(3)
LSM30	Gen <sup>f</sup> , JJH879 <i>attTn7::miniTn7T2.1-Gm-GW::araC-P<sub>BAD</sub>::pelA</i>	(4)
JDR27	Gen <sup>f</sup> , JJH879 <i>attTn7::miniTn7T2.1-Gm-GW::araC-P<sub>BAD</sub>::pelA<sup>E218A</sup></i>	This study
JDR82	Gen <sup>f</sup> , JJH879 <i>attTn7::miniTn7T-Gm</i>	This study
PA14	Wild type strain	(2)
GBW29	PA14 $\Delta_{pelF}$	This study
ER1	PA14 $\Delta_{pelA}$	This study
ER2	PA14 <i>pelA<sup>E218A</sup></i>	This study
<i>gacA</i> SW7.4	Kan <sup>r</sup> , PA14 <i>gacA::aphA-3</i> , non-polar insertion interrupting <i>gacA</i>	(5)
<i>Escherichia coli</i>		
DH5 $\alpha$	<i>F<sup>-</sup> <math>\Phi</math>80lacZ<math>\Delta</math>M15 <math>\Delta</math>(lacZYA-argF) U169 recA1 endA1 hsdR17 (<i>rK<sup>-</sup></i>, <i>mK<sup>+</sup></i>) phoA supE44 <math>\lambda</math>- <i>thi-1</i> gyrA96 relA1</i>	Invitrogen
SM10 ( $\lambda_{pir}$ )	Kan <sup>R</sup> , Tet <sup>R</sup> . <i>thi thr leu tonA lacY supE recA::RP4-2-Tc::Mu K<sub>m</sub> <math>\lambda_{pir}</math></i>	(6)
<i>ccdB</i> Survival 2 <sup>TM</sup> T1R	Str <sup>R</sup> , strain for cloning plasmids with Gateway donor sites	Invitrogen
XL1-Gold	Strain for cloning	Agilent Technologies

<sup>1</sup>Abbreviations for antibiotic selection: Gen, gentamicin; Kan, kanamycin; Str, streptomycin; Tet, tetracycline.

**Supplementary Table 2: Plasmids used in this study.**

Plasmids	Genotype or relevant characteristics <sup>1</sup>	Source
<b>Allelic exchange vectors</b>		
pEX18Gm	Gen <sup>R</sup> , suicide vector for allelic exchange in <i>P. aeruginosa</i> , SacB, lacZ $\alpha$	(6)
pDONRPEX18Gm	Gen <sup>R</sup> , Cam <sup>R</sup> , pEX18Gm with a Gateway® donor site	(1)
pERA1	Gen <sup>R</sup> , pEX18Gm with <i>P. aeruginosa</i> PA14 $\Delta$ <i>pelA</i>	This study
pERA2	Gen <sup>R</sup> , pEX18Gm with a fragment encoding a portion of <i>P. aeruginosa</i> PA14 <i>pelA</i> (402 bp upstream and 477 bp downstream of E218)	This study
pERA3	Gen <sup>R</sup> , pERA2 with <i>pelA</i> <sup>E218A</sup>	This study
pGBW2	Gen <sup>R</sup> , pDONRPEX18Gm with <i>P. aeruginosa</i> PA14 $\Delta$ <i>pelF</i>	This study
pJH310	Gen <sup>R</sup> , pDONRPEX18Gm with <i>P. aeruginosa</i> PAO1 $\Delta$ <i>pelA</i>	This study
<b>Complementation analysis</b>		
pUC18-mini-Tn7T2.1-Gm-GW	Amp <sup>R</sup> , Gen <sup>R</sup> , Cam <sup>R</sup> , miniTn7 with transcriptional terminators flanking the Tn7 transposon; Gateway destination vector	(7)
pUC18T-miniTn7T-Gm	Amp <sup>R</sup> , Gen <sup>R</sup> , miniTn7 vector	(8)
pTNS2	Amp <sup>R</sup> , helper plasmid encoding <i>tnsABCD</i>	(8)
pCAS4	Gen <sup>R</sup> , Amp <sup>R</sup> , pUC18-miniTn7T2.1-Gm-GW with <i>araC</i> - <i>P</i> <sub>BAD</sub> :: <i>pelA</i> in the Gateway cloning site	(4)
pJDR40	Gen <sup>R</sup> , Amp <sup>R</sup> , pCAS4 with <i>P</i> <sub>BAD</sub> :: <i>pelA</i> <sup>E218A</sup>	This study
pPSV39	Gen <sup>R</sup> , expression vector with <i>lacI</i> and <i>lacUV5</i> promoter derived from pPSV35	(9)
pERA4	Gen <sup>R</sup> , RBS and full-length <i>pelA</i> from <i>P. aeruginosa</i> PA14 in pPSV39	This study

<sup>1</sup>Abbreviations for antibiotic selection: Amp, ampicillin; Cam, chloramphenicol; Kan, kanamycin; Gen, gentamicin.

### Supplementary Table 3: Primers used in this study.

Primer name or identifier	Sequence <sup>1</sup>
<b>Sequencing primers</b>	
oER1_pelAF-SEQ	<u>CGG CGA AAA CCT GCG GTG TT</u>
oER2_pelAR-SEQ	<u>CGG CCA GTT CGG CAA AGG T</u>
oJH1472_pelFF01-SEQ	<u>CTA CTC GAT GCT CGA CCA GAA G</u>
oJH1473_pelFR01-SEQ	<u>GAT GCG TTT GTA GGC CTT CAT TC</u>
M13F(-20)	<u>GT AAA ACG ACG GCC AGT</u>
M13R(-27)	<u>CAG GAA ACA GCT ATG AC</u>
oJDR33_araC-ParaBAD-500F01-SEQ	<u>GGT GCG CTT CAT CCG GGC G</u>
oJDR34_araC-ParaBAD-1000F01-SEQ	<u>GCA TTC TGT AAC AAA GCG G</u>
oJDR35_PelA-308R01-SEQ	<u>CGA TGG CGG CGG CGT CG</u>
oJDR36_PelA-770R01-SEQ	<u>GCG GCA GGT AGT CGA TGG CG</u>
oJDR37_PelA-1308R01-SEQ	<u>GCC GGC AGG TCG CGG ATC CG</u>
oJDR38_PelA-1808R01-SEQ	<u>CTG CCA GAA GAA CGG ATG G</u>
oJDR39_PelA-2308R01-SEQ	<u>GGT GCA TGG TGC GGA TCG</u>
oJDR40_PelA-2808R01-SEQ	<u>CAT CGC GCA CCT GCT CCA TC</u>
oJH373_PglmS-down	<u>GCA CAT CGG CGA CGT GCT CTC</u>
oJH374_PglmS-up	<u>CTG TGC GAC TGC TGG AGC TGA</u>
oJH371_PTn7R	<u>CAC AGC ATA ACT GGA CTG ATT TC</u>
oJH372_Tn7L	<u>ATT AGC TTA CGA CGC TAC ACC C</u>
<b>Construction of allelic exchange vectors</b>	
oER3_pelAupF-EcoRI	GGG <b>GAA TTC</b> <u>GCC TGG AAA GGA CAA CCT GA</u>
oER4_pelAupR	<u>CGC GCA CCT GCT CCA TCG GCA A</u> <u>TCC TTT CTT GCT GAA CCG</u> <u>CAT</u>
oER5_pelAdownF	<u>TTG CCG ATG GAG CAG GTG CGC G</u>
oER6_pelAdownR-HindIII	GGG <b>AAG CTT</b> <u>TTC GAG CAT GGC GTC GTT CA</u>

oJJH1419\_pelAupF03-GWB1      GGG **GAC AAG TTT GTA CAA AAA AGC AGG CTA** CGA GCT TTC CCA  
GTT CGA CTG

oJJH1415\_pelAupR01      CCA TCG CGC ACC TGC TCC ATC GGG GCA GTG CCG GCA CAA AG

oJJH1416\_pelAdownF01      CCG ATG GAG CAG GTG CG

oJJH1417\_pelAdownR01-GWB2      GGG **GAC CAC TTT GTA CAA GAA AGC TGG GTA** CAA GGA TGT CCA  
GTT CCA CC

oJJH1435\_pelFupF01-GWB1      GGG **GAC AAG TTT GTA CAA AAA AGC AGG CTA** CGC TGG TAC TGG  
GAA CTG GC

oJJH1436\_pelFupR01      GCA ATC TCC GTG GCT TCG CGG TAC AGC GGA GCG GTG TGT TCG  
GTC

oJJH1437\_pelFdownF01      CTG TAC CGC GAA GCC ACG G

oJJH1438\_pelFdownR01-GWB2      GGG **GAC CAC TTT GTA CAA GAA AGC TGG GTA** CAG GGT CGC CAG  
CAA TAT CG

oER7\_pelA-E218A-upF-EcoRI      GGG **GAA TTC** GGG TAT CTG AAA GAG CAG GGC

oER8\_pelA-E218A-downR-HindIII      GGG **AAG CTT** GAT CCA GTT GTC GAA GGC GTC

### Site Directed Mutagenesis

oJJH1505\_pelA-E218A-F01      GCG GTG GCC GTG GcG TCG ATC CAT GCC

oJJH1506\_pelA-E218A-R01      GGC ATG GAT CGA CgC CAC GGC CAC CGC

oER9\_pelA-E218A-F      TCG GCG GTG GCC GTG GcG TCG ATC CAT GCC GGT

oER10\_pelA-E218A-R      ACC GGC ATG GAT CGA CgC CAC GGC CAC CGC CGA

---

<sup>1</sup>Restriction and attachment sites are bolded; regions complementary to the target amplicon are underlined; regions of reverse complementarity (to facilitate splicing) are italicized; lowercase letters denote a nucleotide substitution.

## Supplementary references

1. **Harrison JJ, Almblad H, Irie Y, Wolter DJ, Eggleston HC, Randall TE, Kitzman JO, Stackhouse B, Emerson JC, Mcnamara S, Larsen TJ, Shendure J, Hoffman LR, Wozniak DJ, Parsek MR.** 2020. Elevated exopolysaccharide levels in *Pseudomonas aeruginosa* flagellar mutants have implications for biofilm growth and chronic infections. *PLoS Genet* **16**:1–22.
2. **Colvin KM, Alnabelseya N, Baker P, Whitney JC, Howell PL, Parsek MR.** 2013. PelA Deacetylase Activity Is Required for Pel Polysaccharide Synthesis in *Pseudomonas aeruginosa*. *J Bacteriol* **195**:2329–2339.
3. **Whitfield GB, Marmont LS, Ostaszewski A, Rich JD, Whitney JC, Parsek MR, Harrison JJ, Howell PL.** 2020. Pel Polysaccharide Biosynthesis Requires an Inner Membrane Complex Comprised of PelD, PelE, PelF, and PelG. *J Bacteriol* **202**:471–18.
4. **Marmont LS, Whitfield GB, Rich JD, Yip P, Giesbrecht LB, Stremick CA, Whitney JC, Parsek MR, Harrison JJ, Howell PL.** 2017. PelA and PelB form a modification and secretion complex essential for Pel polysaccharide-dependent biofilm formation in *Pseudomonas aeruginosa*. *J Biol Chem* jbc.M117.812842–24.
5. **Rahme LG, Tan M-W, Le L, Wong SM, Tompkins RG, Calderwood SB, Ausubel FM.** 1997. Use of model plant hosts to identify *Pseudomonas aeruginosa* virulence factors. *Proc Natl Acad Sci USA* **94**:13245–13250.
6. **Hoang TT, Karkhoff-Schweizer RR, Kutchma AJ, Schweizer HP.** 1998. A broad-host-range F<sub>1</sub>p-FRT recombination system for site-specific excision of chromosomally-located DNA sequences: application for isolation of unmarked *Pseudomonas aeruginosa* mutants. *Gene* **212**:77–86.
7. **Zhao K, Tseng BS, Beckerman B, Jin F, Gibiansky ML, Harrison JJ, Luijten E, Parsek MR, Wong GCL.** 2013. Psl trails guide exploration and microcolony formation in *Pseudomonas aeruginosa* biofilms. *Nature* **497**:388–392.
8. **Choi K-H, Schweizer HP.** 2006. mini-Tn7 insertion in bacteria with single attTn7 sites: example *Pseudomonas aeruginosa*. *Nat Protoc* **1**:153–161.
9. **Rietsch A, Vallet-Gely I, Dove SL, Mekalanos JJ.** 2005. ExsE, a secreted regulator of type III secretion genes in *Pseudomonas aeruginosa*. *Proc Natl Acad Sci USA* **22**:8006–8011.